Drugs / Fruquintinib
Fruquintinib
also known as
ELUNATE · HMPL-013 · fruquintinib+chemotherapy · Aiutec · Fruquintinib Capsules · Fruzaqla · TAK-113
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Fruzaqla | — | 2024-06-20 | europa.eu ↗ |
| Approved | US (FDA) | FRUZAQLA | — | 2023-11-08 | fda.gov ↗ |
Trials 164 · started per year
today
US approved 2023
EU approved 2024
1
2
2
2
2
1
6
8
14
25
32
26
26
16
201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06380309 | May 2024 → Dec 2025 overdue | digestive system cancer | Peking University | Recruiting | No outcome recorded |
| Phase 112 trials | ||||||
| Phase 1 | NCT05848739 | Jun 2023 → May 2026 overdue | colorectal cancer | Sapience Therapeutics | Recruiting | No outcome recorded |
| Phase 1 | NCT05216354 | Mar 2022 → Jun 2023 | impaired renal function disease | Hutchmed | Completed | No outcome recorded |
| Phase 1 | NCT05216367 | Mar → Oct 2022 | — | Hutchmed | Completed | No outcome recorded |
| Phase 1 | NCT05368805 | Mar → Apr 2022 | colorectal cancer | Hutchmed | Completed | No outcome recorded |
| Phase 1 | NCT04645940 | Sep → Nov 2020 | — | Hutchison Medipharma Limited | Completed | No outcome recorded |
| Phase 1 | NCT04557397 | Sep → Oct 2020 | — | Hutchison Medipharma Limited | Completed | No outcome recorded |
| Phase 1 | NCT03976856 | Jul 2019 → Dec 2021 | non-small cell lung carcinoma | Genor Biopharma Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT03977090 | Apr 2019 → Dec 2021 | colorectal cancer | Genor Biopharma Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT03251378 | Dec 2017 → Dec 2022 | hormone receptor-positive breast cancer, malignant colon neoplasm, rectal cancer, triple-negative breast carcinoma | Hutchison Medipharma Limited | Completed | No outcome recorded |
| Phase 1 | NCT02689752 | Jul → Sep 2016 | — | Hutchison Medipharma Limited | Completed | No outcome recorded |
| Phase 1 | NCT01955304 | Jun → Sep 2012 | — | Hutchison Medipharma Limited | Completed | No outcome recorded |
| Phase 1 | NCT01645215 | Jan 2011 → Oct 2012 | neoplasm | Hutchison Medipharma Limited | Completed | No outcome recorded |
| Phase 1/221 trials | ||||||
| Phase 1/2 | NCT07621159 | Jul 2026 → Nov 2027 expected | colorectal cancer | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07591597 | May 2026 → Jul 2027 expected | colorectal cancer | National Cancer Center Hospital East | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07025850 | Aug 2025 → Jan 2027 expected | colorectal carcinoma | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06980532 | Apr 2025 → Dec 2028 expected | colorectal cancer | Liu Huang | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06871527 | Mar 2025 → Mar 2028 expected | gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | Sixth Affiliated Hospital, Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06484153 | Jul 2024 → Jul 2026 overdue | — | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06329973 | Feb 2024 → Jun 2026 overdue | gastroesophageal junction adenocarcinoma | Henan Cancer Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07334431 | Feb 2024 → Dec 2025 overdue | gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | Henan Cancer Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06195670 | Jan 2024 → Jan 2026 overdue | colorectal adenocarcinoma | Zhejiang Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06078670 | Oct 2023 → Jun 2026 | neoplasm | Fujian Cancer Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT06010212 | Aug 2023 → Aug 2025 | esophageal squamous cell carcinoma | The First Affiliated Hospital with Nanjing Medical University | Unknown | No outcome recorded |
| Phase 1/2 | NCT07491159 | Jul 2023 → Jun 2026 overdue | colorectal cancer | Tianjin Medical University Cancer Institute and Hospital | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05982834 | May 2023 → May 2025 | carcinoma | Fudan University | Unknown | No outcome recorded |
| Phase 1/2 | NCT05522738 | Aug 2022 → Dec 2024 | colorectal cancer | Chinese PLA General Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT05024812 | Jun 2022 → Aug 2023 | gastric cancer | The First Affiliated Hospital of Zhengzhou University | Unknown | No outcome recorded |
| Phase 1/2 | NCT05016869 | Apr 2022 → Feb 2023 | colorectal cancer | Chinese Academy of Medical Sciences | Unknown | No outcome recorded |
| Phase 1/2 | NCT04577963 | Aug 2021 → Jun 2024 | colorectal cancer, endometrial cancer, triple-negative breast carcinoma | Hutchmed | Terminated | No outcome recorded |
| Phase 1/2 | NCT04446091 | Jul 2020 → Jul 2021 | colorectal cancer | Zhejiang Cancer Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT03903705 | Apr 2019 → Nov 2023 | neoplastic disease or syndrome | Hutchmed | Completed | No outcome recorded |
| Phase 1/2 | NCT02415023 | Nov 2014 → Mar 2017 | gastric cancer | Hutchison Medipharma Limited | Completed | No outcome recorded |
| Phase 1/2 | NCT01975077 | Dec 2012 → Apr 2014 | colorectal cancer | Hutchison Medipharma Limited | Completed | No outcome recorded |
| Phase 2101 trials | ||||||
| Phase 2 | NCT07689292 | Jul 2026 → Aug 2027 expected | gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07622550 | Jun 2026 → Dec 2027 expected | colorectal cancer | Jiangsu Cancer Institute & Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07658872 | Jun 2026 → May 2027 expected | gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | Sichuan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07510932 | May 2026 → Mar 2027 expected | colon carcinoma | Korea University Anam Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07502014 | May 2026 → Dec 2028 expected | colorectal cancer | Huazhong University of Science and Technology | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07515820 | Apr 2026 → Jul 2027 expected | colorectal cancer | Meng Qiu | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06889610 | Mar 2026 → Dec 2027 expected | colorectal cancer, melanoma, triple-negative breast carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT07042685 | Jan 2026 → Dec 2028 expected | colorectal cancer | The Methodist Hospital Research Institute | Recruiting | No outcome recorded |
| Phase 2 | NCT07353268 | Jan 2026 → Aug 2027 expected | colorectal cancer | Tao Zhang | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07150403 | Dec 2025 → Feb 2028 expected | colorectal carcinoma | Federation Francophone de Cancerologie Digestive | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07286695 | Dec 2025 → Dec 2029 expected | colorectal cancer | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07392346 | Dec 2025 → Nov 2027 expected | gastric adenocarcinoma | Dai, Guanghai | Recruiting | No outcome recorded |
| Phase 2 | NCT07261709 | Dec 2025 → Oct 2027 expected | colorectal cancer | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07229872 | Dec 2025 → Dec 2026 expected | colorectal cancer | Harbin Medical University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06856837 | Oct 2025 → Dec 2029 expected | colorectal cancer | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Recruiting | No outcome recorded |
| Phase 2 | NCT06992258 | Oct 2025 → Dec 2027 expected | colorectal cancer | Criterium, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT07170982 | Oct 2025 → Oct 2027 expected | endometrial cancer | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07011576 | Sep 2025 → Jan 2027 expected | colon carcinoma, rectal carcinoma | SCRI Development Innovations, LLC | Recruiting | No outcome recorded |
| Phase 2 | NCT07136077 | Sep 2025 → Dec 2027 expected | colorectal cancer | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT07130903 | Sep 2025 → Apr 2028 expected | colorectal adenocarcinoma | Barbara Ann Karmanos Cancer Institute | Recruiting | No outcome recorded |
| Phase 2 | NCT07488533 | Aug 2025 → Dec 2027 expected | nonpapillary renal cell carcinoma | Sun Yat-sen University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT07051785 | Jul 2025 → Jul 2027 expected | colorectal cancer | Liu Huang | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06973421 | Jul 2025 → Jun 2027 expected | refractory malignant neoplasm | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05690035 | Jul 2025 | colorectal cancer, metastatic malignant neoplasm in the colon | Sun Yat-sen University | Withdrawn | No outcome recorded |
| Phase 2 | NCT07003022 | Jun 2025 → May 2027 expected | colorectal cancer | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT06888037 | Mar 2025 → Mar 2028 expected | gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | Ruijin Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06746545 | Feb 2025 → Aug 2026 overdue | colorectal cancer | Fujian Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06979908 | Jan 2025 → Jul 2026 overdue | colorectal cancer | The First Hospital of Jilin University | Recruiting | No outcome recorded |
| Phase 2 | NCT06446154 | Dec 2024 → Dec 2025 overdue | hepatocellular carcinoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 2 | NCT06706895 | Dec 2024 → Dec 2025 overdue | gastric cancer | Shanghai Zhongshan Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06685276 | Aug 2024 → Dec 2025 overdue | colorectal cancer | Dai, Guanghai | Recruiting | No outcome recorded |
| Phase 2 | NCT06513221 | Jul 2024 → Apr 2026 overdue | colorectal cancer | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06487702 | Jul 2024 → Jun 2026 overdue | esophageal squamous cell carcinoma | Rui-hua Xu, MD, PhD | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06791083 | Jun 2024 → Dec 2025 overdue | gastric cancer | First Affiliated Hospital of Fujian Medical University | Recruiting | No outcome recorded |
| Phase 2 | NCT06218888 | Jun 2024 → Dec 2025 overdue | colorectal cancer | Fujian Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06406426 | May 2024 → May 2025 overdue | gastroesophageal junction adenocarcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT06423937 | May 2024 → Jul 2026 overdue | colorectal cancer | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06356597 | Apr 2024 → Dec 2026 expected | colorectal cancer | Jing-yuan Fang, MD, Ph. D | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06356584 | Apr 2024 → Oct 2026 expected | metastasis from malignant tumor of colon | Shandong Cancer Hospital and Institute | Recruiting | No outcome recorded |
| Phase 2 | NCT06646588 | Apr 2024 → Apr 2026 overdue | neoplasm of esophagus | Hebei Medical University Fourth Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06543836 | Dec 2023 → Nov 2025 overdue | colorectal cancer | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Recruiting | No outcome recorded |
| Phase 2 | NCT06234007 | Dec 2023 → Dec 2024 overdue | — | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Recruiting | No outcome recorded |
| Phase 2 | NCT06148402 | Nov 2023 → Dec 2025 | colorectal cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Unknown | No outcome recorded |
| Phase 2 | NCT06010888 | Oct 2023 → Oct 2024 | colorectal cancer | Fudan University | Unknown | No outcome recorded |
| Phase 2 | NCT06091423 | Oct 2023 → Nov 2025 overdue | gastroesophageal junction adenocarcinoma | Xiaofeng Chen | Recruiting | No outcome recorded |
| Phase 2 | NCT05842525 | Oct 2023 → May 2024 | colorectal cancer | Hunan Cancer Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT06094868 | Oct 2023 → Oct 2026 expected | gastric cancer | Second Affiliated Hospital of Nanchang University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06774222 | Sep 2023 → Dec 2025 overdue | gastroesophageal adenocarcinoma | Henan Cancer Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT05954429 | Jul 2023 → Dec 2026 expected | colorectal cancer | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT05571644 | Jul 2023 → Dec 2025 overdue | colorectal cancer | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 2 | NCT06168786 | Jun 2023 → Feb 2026 overdue | colorectal cancer | Huazhong University of Science and Technology | Recruiting | No outcome recorded |
| Phase 2 | NCT05555901 | Jun 2023 → Sep 2025 | colorectal cancer | Fudan University | Unknown | No outcome recorded |
| Phase 2 | NCT06018714 | May 2023 → Aug 2024 overdue | colorectal cancer | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 2 | NCT05831891 | May 2023 → Jul 2026 overdue | renal cell carcinoma | RenJi Hospital | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05941325 | Apr 2023 → Dec 2026 | sarcoma | Shanghai 6th People's Hospital | Suspended | No outcome recorded |
| Phase 2 | NCT05721651 | Apr 2023 → Mar 2025 | gastric cancer | Wu Jun | Unknown | No outcome recorded |
| Phase 2 | NCT05771181 | Mar 2023 → Dec 2025 overdue | colorectal carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT05747716 | Feb 2023 → Dec 2026 expected | colorectal cancer | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06427005 | Feb 2023 → Aug 2025 | — | Meng Qiu | Unknown | No outcome recorded |
| Phase 2 | NCT07024537 | Jan 2023 → May 2025 | colorectal neoplasm | Meng Qiu | Completed | No outcome recorded |
| Phase 2 | NCT05659290 | Jan 2023 → Dec 2025 | colorectal cancer | Nanfang Hospital, Southern Medical University | Unknown | No outcome recorded |
| Phase 2 | NCT05795296 | Dec 2022 → Aug 2024 | gastric neoplasm | RenJi Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT05643677 | Dec 2022 → Nov 2024 | gastric cancer | Fujian Medical University | Unknown | No outcome recorded |
| Phase 2 | NCT05634590 | Dec 2022 → Dec 2025 | colorectal cancer | Fudan University | Unknown | No outcome recorded |
| Phase 2 | NCT05575635 | Nov 2022 → May 2024 | rectal cancer | Henan Provincial People's Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT05625737 | Sep 2022 → Dec 2024 | gastric neoplasm | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Unknown | No outcome recorded |
| Phase 2 | NCT05763927 | Sep 2022 → Oct 2024 | rectal cancer | West China Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT05447715 | Aug 2022 → Dec 2024 | colorectal cancer | Weijian Guo | Unknown | No outcome recorded |
| Phase 2 | NCT05279677 | Aug 2022 → Oct 2023 | colorectal cancer | Chinese Academy of Medical Sciences | Unknown | No outcome recorded |
| Phase 2 | NCT05435313 | Jul 2022 → Jan 2024 | colorectal cancer | Fudan University | Unknown | No outcome recorded |
| Phase 2 | NCT05451719 | Jul 2022 → Jul 2024 | colorectal cancer | Fudan University | Unknown | No outcome recorded |
| Phase 2 | NCT05177068 | May 2022 → Oct 2024 overdue | gastric cancer | Henan Cancer Hospital | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05241899 | May 2022 → May 2023 | gastric cancer | The First Affiliated Hospital of Zhengzhou University | Unknown | No outcome recorded |
| Phase 2 | NCT05636150 | Mar 2022 → Mar 2024 | esophageal squamous cell carcinoma | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT05292417 | Mar 2022 → Mar 2023 | colorectal carcinoma | The First Affiliated Hospital of Xiamen University | Unknown | No outcome recorded |
| Phase 2 | NCT05004831 | Mar 2022 → Sep 2023 | colorectal cancer | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 2 | NCT05406206 | Feb 2022 → Jul 2023 | colorectal carcinoma, metastasis from malignant tumor of colon | Peking University Cancer Hospital & Institute | Unknown | No outcome recorded |
| Phase 2 | NCT04956146 | Feb 2022 → Sep 2023 | non-small cell lung carcinoma | The First Affiliated Hospital with Nanjing Medical University | Unknown | No outcome recorded |
| Phase 2 | NCT05257122 | Feb 2022 → Sep 2023 | — | Fudan University | Unknown | No outcome recorded |
| Phase 2 | NCT04866108 | Dec 2021 → Jun 2024 | colorectal cancer | Beijing Friendship Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT05971199 | Nov 2021 → Dec 2024 | hepatocellular carcinoma | Zhejiang Cancer Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT05142631 | Nov 2021 → May 2023 | soft tissue sarcoma | Fudan University | Unknown | No outcome recorded |
| Phase 2 | NCT05122091 | Nov 2021 → Nov 2024 | gastric cancer, gastroesophageal cancer | Guangxi Medical University | Unknown | No outcome recorded |
| Phase 2 | NCT05168527 | Sep 2021 → Mar 2024 | malignant pancreatic neoplasm | Fudan University | Unknown | No outcome recorded |
| Phase 2 | NCT04948034 | Aug 2021 → Dec 2022 | colorectal cancer | Fudan University | Unknown | No outcome recorded |
| Phase 2 | NCT04989855 | Aug 2021 → Aug 2022 | — | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 2 | NCT05004441 | Jul 2021 → Dec 2022 | colorectal cancer | Zhou Fuxiang | Unknown | No outcome recorded |
| Phase 2 | NCT04924179 | Jun 2021 → Dec 2022 | colorectal cancer | Huazhong University of Science and Technology | Unknown | No outcome recorded |
| Phase 2 | NCT04866862 | Apr 2021 → Jun 2024 | colorectal neoplasm | The First Affiliated Hospital with Nanjing Medical University | Unknown | No outcome recorded |
| Phase 2 | NCT04716634 | Apr 2021 → Feb 2024 | cancer | BeiGene | Completed | No outcome recorded |
| Phase 2 | NCT04733963 | Mar 2021 → Jan 2023 | colorectal cancer | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 2 | NCT04296019 | Feb 2021 → Jul 2023 | colorectal cancer | Shanghai Zhongshan Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT05025631 | Nov 2020 → Oct 2022 | colorectal cancer | Zhen-Yu Ding | Completed | No outcome recorded |
| Phase 2 | NCT04582981 | Sep 2020 → Jun 2023 | colorectal carcinoma | Fudan University | Unknown | No outcome recorded |
| Phase 2 | NCT04695470 | Sep 2020 → Dec 2021 | colorectal cancer | Aiping Zhou | Unknown | No outcome recorded |
| Phase 2 | NCT04483219 | Jul 2020 → Jul 2022 | colorectal adenocarcinoma | China Medical University, China | Unknown | No outcome recorded |
| Phase 2 | NCT04156958 | Dec 2019 → Sep 2021 | biliary tract cancer | Sichuan University | Unknown | No outcome recorded |
| Phase 2 | NCT04179084 | Aug 2019 → Mar 2020 | colorectal cancer | Chinese PLA General Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT03684967 | May 2018 → Sep 2019 | lung cancer | Hutchison Medipharma Limited | Withdrawn | No outcome recorded |
| Phase 2 | NCT02976116 | Dec 2016 → Jun 2019 | non-small cell lung carcinoma | Hutchison Medipharma Limited | Completed | No outcome recorded |
| Phase 2 | NCT02590965 | May 2014 → Aug 2015 | non-small cell lung carcinoma | Hutchison Medipharma Limited | Completed | No outcome recorded |
| Phase 2/34 trials | ||||||
| Phase 2/3 | NCT06977061 | Jun 2025 → Jun 2026 overdue | gastric neoplasm | Queling Liu | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT06443671 | Jun 2024 → Jun 2026 overdue | rectal cancer | Peking University Cancer Hospital & Institute | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT06441565 | May 2024 → Dec 2025 overdue | colorectal cancer | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05522231 | Oct 2022 → Jan 2025 overdue | renal cell carcinoma | Hutchmed | Active not recruiting | No outcome recorded |
| Phase 39 trials | ||||||
| Phase 3 | NCT07483684 | Mar 2026 → Aug 2027 expected | carcinoma | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07362836 | Jan 2026 → Dec 2028 expected | colorectal cancer | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07270991 | Dec 2025 → Nov 2030 expected | gastroesophageal adenocarcinoma | Federation Francophone de Cancerologie Digestive | Recruiting | No outcome recorded |
| Phase 3 | NCT06584032 | Dec 2024 → Jan 2029 expected | endometrial cancer | Hutchmed | Recruiting | No outcome recorded |
| Phase 3 | NCT06199973 | Mar 2024 → Apr 2026 overdue | colorectal cancer | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05914610 | Sep 2023 → Jul 2025 overdue | gastric cancer | Fujian Medical University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT04322539 | Aug 2020 → Jul 2022 | colorectal cancer, metastatic malignant neoplasm in the colon | Hutchison Medipharma Limited | Completed | No outcome recorded |
| Phase 3 | NCT04164199 | Dec 2019 → May 2026 | cancer | BeOne Medicines | Completed | No outcome recorded |
| Phase 3 | NCT03223376 | Oct 2017 → Sep 2022 | gastric cancer | Hutchison Medipharma Limited | Completed | No outcome recorded |
| Phase 44 trials | ||||||
| Phase 4 | NCT07446465 | Mar 2026 → Jan 2027 expected | colorectal cancer | Ye Xu | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06562543 | Jan 2025 → Oct 2027 expected | colorectal cancer | Takeda | Recruiting | No outcome recorded |
| Phase 4 | NCT06118762 | Oct 2023 → Oct 2026 expected | colorectal cancer | The First Affiliated Hospital of Nanchang University | Recruiting | No outcome recorded |
| Phase 4 | NCT05661357 | Jan 2023 → Jan 2025 | colorectal cancer | Zhongnan Hospital | Unknown | No outcome recorded |
| Phase not applicable11 trials | ||||||
| — | NCT07552402 | Jun 2026 → Dec 2027 expected | gastroesophageal junction adenocarcinoma | Harbin Medical University | Recruiting | No outcome recorded |
| — | NCT07124858 | Mar 2026 → Mar 2031 expected | colorectal cancer | Federation Francophone de Cancerologie Digestive | Recruiting | No outcome recorded |
| — | NCT06985316 | May 2025 → Apr 2028 expected | colorectal cancer | Liu Huang | Not yet recruiting | No outcome recorded |
| — | NCT06553781 | Sep 2024 → Sep 2025 overdue | melanoma | Fudan University | Not yet recruiting | No outcome recorded |
| — | NCT06551207 | Aug 2024 → Dec 2026 expected | colorectal cancer | Liu Huang | Recruiting | No outcome recorded |
| — | NCT06613113 | Aug 2024 → Apr 2025 overdue | colorectal cancer | Ningbo Medical Center Lihuili Hospital | Recruiting | No outcome recorded |
| — | NCT06317298 | Feb 2024 → Aug 2025 | clear cell renal carcinoma | Peking University First Hospital | Unknown | No outcome recorded |
| — | NCT06199232 | Jan 2024 → Jun 2026 overdue | metastasis from malignant tumor of colon | Peking University | Active not recruiting | No outcome recorded |
| — | NCT06115733 | Dec 2023 → Dec 2026 expected | colorectal carcinoma | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Not yet recruiting | No outcome recorded |
| — | NCT06158919 | Nov 2023 → Nov 2024 overdue | gastroesophageal junction adenocarcinoma | Fudan University | Recruiting | No outcome recorded |
| — | NCT05928312 | Aug 2023 → Jun 2025 | colorectal cancer | Zhejiang Cancer Hospital | Unknown | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT06195514 | — | colorectal cancer | Takeda | No longer available | No outcome recorded |
Also used as a comparator or background therapy in 13 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06347198 Background | Apr → Dec 2024 | colorectal cancer | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Unknown | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT05867420 Background | Aug 2023 → Dec 2026 expected | cancer | AskGene Pharma, Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05565417 Background | Nov 2022 → Jan 2026 overdue | Burkitt lymphoma, Hodgkins lymphoma, colorectal cancer, diffuse large B-cell lymphoma +8 | Immunitas Therapeutics | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05405595 Background | Jun 2022 → Oct 2026 expected | — | Adagene Inc | Recruiting | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT07535632 Comparator | Jun 2026 → Jun 2028 expected | colorectal neoplasm | Shanghai Zhongshan Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07235293 Comparator | Jan → Sep 2026 expected | colorectal cancer | Kahr Bio Australia Pty Ltd | Recruiting | No outcome recorded |
| Phase 2 | NCT07257653 Background | Oct 2025 → Dec 2026 expected | colorectal adenocarcinoma | Zhejiang University | Recruiting | No outcome recorded |
| Phase 2 | NCT05511051 Background | Feb 2022 → Aug 2024 | colorectal cancer | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Unknown | No outcome recorded |
| Phase 2 | NCT02196688 Comparator | Apr 2014 → Apr 2015 | colorectal cancer | Hutchison Medipharma Limited | Completed | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT07384377 Comparator | Feb 2026 → Nov 2027 expected | carcinoma | Shanghai JMT-Bio Inc. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06497985 Comparator | Dec 2024 → May 2028 expected | colorectal cancer | Chipscreen Biosciences, Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT02691299 Comparator | Dec 2015 → Sep 2018 | non-small cell lung carcinoma | Hutchison Medipharma Limited | Completed | No outcome recorded |
| Phase 3 | NCT02314819 Comparator | Dec 2014 → Jan 2017 | colorectal cancer | Hutchison Medipharma Limited | Completed | No outcome recorded |
Press releases naming this drug 7 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-09-24 | Takeda | Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer takeda.com ↗ |
| 2024-06-21 | Takeda | Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer takeda.com ↗ |
| 2024-04-26 | Takeda | Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer takeda.com ↗ |
| 2023-11-08 | Takeda | Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer takeda.com ↗ |
| 2023-06-15 | Takeda | Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency takeda.com ↗ |
| 2023-05-25 | Takeda | Takeda and HUTCHMED Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review takeda.com ↗ |
| 2023-01-23 | Takeda | Takeda To Acquire Exclusive Worldwide (ex-China) License of HUTCHMED’s Fruquintinib, a Highly Selective, Oral VEGFR1/2/3 Tyrosine Kinase Inhibitor takeda.com ↗ |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 181 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fruquintinib | “Phase II Clinical Study of Digoxin Combined With Fruquintinib and Tislelizumab in Patients With Advanced Primary Colorectal Cancer Who Failed Standard Therapy” NCT07025850 ↗175“Fruquintinib (Group B, KRAS/NRAS/BRAF/EGFR mutation type and wide type but treated with cetuximab in last 3 months): 3 mg/d, d3-23, then suspend for 1w.” NCT06199232 ↗ “Fruquintinib Plus Nab-Paclitaxel and Iparomlimab and Tuvonralimab Injection are administered until disease progression or toxicity intolerable.” NCT07392346 ↗ “Fruquintinib is an oral small molecule inhibitor of VEGFR1/2/3, has approved for the third-line treatment of refractory colorectal cancer.” NCT05842525 ↗ “All patients received oral fruquintinib at an initial dose of 4 mg once daily from day 1 to day 21 of each 28-day cycle” NCT07024537 ↗ “combination therapy with IDOV-SAFE + Toripalimab + Fruquintinib after progression on IDOV-SAFETM monotherapy.” NCT06380309 ↗ “Multimodal ablation combined with cadonilimab and fruquintinib” NCT06889610 ↗ “Fruquintinib 5mg or regorafenib 120mg, qd po, 3 weeks, Q4w.” NCT04483219 ↗ “Fruquintinib: qd po, 4mg/d, 2weeks on/1 week off, q3w” NCT06195670 ↗ “Fruquintinib:5mg,po.qd,Day1\~21, repeat every 28 days” NCT04446091 ↗ “Fuquinitinib capsule (Aiutec, Fruquintinib)” NCT06078670 ↗ “Fruquintinib: 4mg po” NCT06513221 ↗ |
| Known as | Aiutec | “Fuquinitinib capsule (Aiutec, Fruquintinib)” NCT06078670 ↗ |
| Known as | ELUNATE | “Fruquintinib (Elunate®) is an orally available, potent and highly selective small molecule inhibitor of VEGFR-1, -2 and -3 that was discovered and developed by Hutchison...” PMID 30357594 ↗ Nov 20182“Fruquintinib (trade name: Elunate) is a novel small molecule tyrosine kinase inhibitor.” NCT04156958 ↗ “Fruquintinib (ELUNATE®) is a novel kinase inhibitor” PMID 36623495 ↗ Jan 2023 |
| Known as | Fruquintinib Capsules | “Fruquintinib Capsules：4 mg / day, orally once daily on days 1-14 in 21-day cycles.” NCT06706895 ↗ |
| Known as | fruquintinib+chemotherapy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07362836 ↗ |
| Known as | Fruzaqla | ChEMBL registry synonym — accepted as the source's own label CHEMBL4303214 ↗ |
| Known as | HMPL-013 | “whether fruquintinib(HMPL-013) plus sintilimab(IBI308) is safe and effective in the treatment of advanced endometrial cancer(EMC).” NCT06584032 ↗2“Study of Fruquintinib (HMPL-013) in High Risk Patients With Advanced NSCLC” NCT03684967 ↗ “Fruquintinib (HMPL-013) is a novel oral small molecule compound” PMID 27299749 ↗ Jun 2016 |
| Known as | TAK-113 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06195514 ↗ |
| Action | Inhibit | “selectively inhibits vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3” NCT01645215 ↗ |
| Modality | Small molecule | “novel oral small molecule” NCT01645215 ↗ |
| Route | Oral | “continuous oral dosing” NCT01645215 ↗ |